291 related articles for article (PubMed ID: 18338632)
1. [A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].
Liu SN; Shen ZF
Yao Xue Xue Bao; 2007 Dec; 42(12):1227-31. PubMed ID: 18338632
[TBL] [Abstract][Full Text] [Related]
2. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation.
Martinez A; Castro A; Dorronsoro I; Alonso M
Med Res Rev; 2002 Jul; 22(4):373-84. PubMed ID: 12111750
[TBL] [Abstract][Full Text] [Related]
3. Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3.
Plotkin B; Kaidanovich O; Talior I; Eldar-Finkelman H
J Pharmacol Exp Ther; 2003 Jun; 305(3):974-80. PubMed ID: 12626660
[TBL] [Abstract][Full Text] [Related]
4. Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic.
Medina M; Castro A
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):533-43. PubMed ID: 18600569
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibitors of glycogen synthase kinase 3.
Meijer L; Flajolet M; Greengard P
Trends Pharmacol Sci; 2004 Sep; 25(9):471-80. PubMed ID: 15559249
[TBL] [Abstract][Full Text] [Related]
6. Oxidative stress-induced insulin resistance in rat skeletal muscle: role of glycogen synthase kinase-3.
Dokken BB; Saengsirisuwan V; Kim JS; Teachey MK; Henriksen EJ
Am J Physiol Endocrinol Metab; 2008 Mar; 294(3):E615-21. PubMed ID: 18089761
[TBL] [Abstract][Full Text] [Related]
7. GSK-3 inhibitors for Alzheimer's disease.
Avila J; Hernández F
Expert Rev Neurother; 2007 Nov; 7(11):1527-33. PubMed ID: 17997701
[TBL] [Abstract][Full Text] [Related]
8. GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease.
Gao C; Hölscher C; Liu Y; Li L
Rev Neurosci; 2011 Dec; 23(1):1-11. PubMed ID: 22718609
[TBL] [Abstract][Full Text] [Related]
9. Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs.
Martinez A
Med Res Rev; 2008 Sep; 28(5):773-96. PubMed ID: 18271054
[TBL] [Abstract][Full Text] [Related]
10. Glycogen synthase kinase 3: a drug target for CNS therapies.
Bhat RV; Budd Haeberlein SL; Avila J
J Neurochem; 2004 Jun; 89(6):1313-7. PubMed ID: 15189333
[TBL] [Abstract][Full Text] [Related]
11. Activator or inhibitor? GSK-3 as a new drug target.
Takahashi-Yanaga F
Biochem Pharmacol; 2013 Jul; 86(2):191-9. PubMed ID: 23643839
[TBL] [Abstract][Full Text] [Related]
12. Judging a protein by more than its name: GSK-3.
Woodgett JR
Sci STKE; 2001 Sep; 2001(100):re12. PubMed ID: 11579232
[TBL] [Abstract][Full Text] [Related]
13. Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease.
Maqbool M; Mobashir M; Hoda N
Eur J Med Chem; 2016 Jan; 107():63-81. PubMed ID: 26562543
[TBL] [Abstract][Full Text] [Related]
14. Glycogen synthase kinase 3: an emerging therapeutic target.
Eldar-Finkelman H
Trends Mol Med; 2002 Mar; 8(3):126-32. PubMed ID: 11879773
[TBL] [Abstract][Full Text] [Related]
15. Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions.
Saraswati AP; Ali Hussaini SM; Krishna NH; Babu BN; Kamal A
Eur J Med Chem; 2018 Jan; 144():843-858. PubMed ID: 29306837
[TBL] [Abstract][Full Text] [Related]
16. CDK/GSK-3 inhibitors as a new approach for the treatment of proliferative renal diseases.
Soos TJ; Meijer L; Nelson PJ
Drug News Perspect; 2006; 19(6):325-8. PubMed ID: 16971968
[TBL] [Abstract][Full Text] [Related]
17. Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment.
Eldar-Finkelman H; Ilouz R
Expert Opin Investig Drugs; 2003 Sep; 12(9):1511-9. PubMed ID: 12943495
[TBL] [Abstract][Full Text] [Related]
18. Glycogen synthase kinase-3 as drug target: from wallflower to center of attention.
Van Wauwe J; Haefner B
Drug News Perspect; 2003 Nov; 16(9):557-65. PubMed ID: 14702136
[TBL] [Abstract][Full Text] [Related]
19. Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α.
Lo Monte F; Kramer T; Gu J; Anumala UR; Marinelli L; La Pietra V; Novellino E; Franco B; Demedts D; Van Leuven F; Fuertes A; Dominguez JM; Plotkin B; Eldar-Finkelman H; Schmidt B
J Med Chem; 2012 May; 55(9):4407-24. PubMed ID: 22533818
[TBL] [Abstract][Full Text] [Related]
20. Glycogen synthase kinase-3 inhibitors augment TRAIL-induced apoptotic death in human hepatoma cells.
Beurel E; Blivet-Van Eggelpoël MJ; Kornprobst M; Moritz S; Delelo R; Paye F; Housset C; Desbois-Mouthon C
Biochem Pharmacol; 2009 Jan; 77(1):54-65. PubMed ID: 18938143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
